Oncology: International Journal of Cancer Research and Treatment
April 2017, Vol.92, No. 4
Camacho X.a, Machado C.L.e, García M.F.a, Gambini J.P.b, Banchero A.a, Fernández M.a, Oddone N.c, Bertolini Zanatta D.f, Rosal C.f, Buchpiguel C.A.e, Chammas R.g, Riva E.d, Cabral P.a
Rituximab was the first monoclonal antibody approved for the treatment of B-cell non-Hodgkin lymphoma (NHL) expressing CD20 antigen. This antibody has also the potential to be used as a specific fluorescent and radiolabel agent for targeting NHL.
To radiolabel rituximab with technetium-99m (99mTc) or Cy7 and evaluate both probes as potential imaging agents for NHL.
Rituximab was derivatized with the trifluoroacetyl hydrazino protected form of succinimidyl ester of HYNIC and radiolabeled with 99mTc. Radiochemical stability and in vitro cell assays were evaluated. Biodistribution and single-photon emission computed tomography/computed tomography (SPECT/CT) were performed. Raji cells were transfected with luciferase for bioluminescent NHL imaging up to 21 days. Rituximab was labeled with Cy7 for in vivo noninvasive fluorescence imaging up to 96 h